Morningstar generic-pharmaceuticals analyst Brian Laegeler discusses the outlook for generic biologics in the U.S. given a strong branded-drug lobby and complex manufacturing processes.
After a strong runup from our recommendation, is it time to take money off the table in Lexicon Pharmaceuticals?
Contract research organization Parexel is exploiting its global footprint to rapidly enroll patients in drug studies.
Shareholders would be well-served by the pharmacy benefit managers' merger, but regulators are unlikely to sign off on it, says Morningstar's Matt Coffina.
Good day ladies and gentlemen and welcome to Jazz Pharmaceuticals Full Year and Fourth Quarter 2011 Financial Results Conference Call. Following an introduction from the Company, we will open the call to questions.
©2012 Morningstar Advisor. All right reserved.